查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2037558

疫苗市場預測—全球疫苗類型、價態、目標疾病、給藥途徑、年齡層、生產模式、儲存與物流、最終用戶、分銷管道和地區分析—2034年

Vaccine Market Forecasts to 2034 - Global Analysis By Vaccine Type, Valency Type, Disease Indication, Route of Administration, Age Group, Manufacturing Model, Storage & Logistics, End User, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

全球疫苗市場預計到 2026 年將達到 914 億美元，並在預測期內以 6.9% 的複合年成長率成長，到 2034 年達到 1559 億美元。

疫苗是能夠提供針對特定感染疾病的獲得性主動免疫的生物製藥，透過預防和根除疾病，在全球公共衛生領域發揮著至關重要的作用。該市場涵蓋多種疫苗，包括兒童、成人疫苗、流感疫苗、新冠疫苗、旅遊疫苗以及針對各種感染疾病的治療性疫苗。感染疾病的日益普及、老年人口的成長（老年人口感染風險較高）、持續的研發投入以及開發中國家免疫規劃的擴展，都在推動這一重要醫療保健市場的持續成長。

感染疾病率上升和大流行威脅

麻疹、登革熱、伊波拉出血熱和新型流感病毒株等感染疾病的反覆出現，不斷凸顯著全球免疫規劃的關鍵重要性。近期爆發的新冠肺炎疫情既展現了新發病原體對經濟和健康造成的毀滅性影響，也展現了快速疫苗研發平台的巨大潛力。這種日益增強的意識促使政府持續投入資金，加快法規核准流程，並使社會對免疫接種的接受度空前提高。新興經濟體面臨著地方性疾病和新興感染疾病的雙重負擔，因此對疫苗的需求尤其強勁，因為在不斷擴大的醫療衛生基礎設施建設中，預防醫學的重要性日益凸顯，超過了被動治療手段。

疫苗研發和低溫運輸物流高成本

研發新疫苗通常需要10到15年，投資額超過10億美元，這對中小型製造商和新興市場的新進業者構成了重大障礙。嚴格的法規環境要求進行涉及不同人群的大規模臨床試驗，這進一步延長了研發時間和增加了資金需求。此外，大多數疫苗對溫度敏感，需要從生產設施到最終接種點的複雜低溫運輸基礎設施。這帶來了巨大的物流挑戰，尤其是在偏遠或資源匱乏的地區。這些成本壓力共同限制了疫苗的市場准入，特別是對於那些主要針對低收入地區流行疾病的疫苗而言，因為這些地區的消費者難以負擔高昂的價格。

mRNA和新型平台技術的擴展

新冠疫情期間mRNA疫苗的顯著成功徹底改變了疫苗研發模式，為快速應對新威脅和以往難以攻克的難題開闢了前所未有的機會。與傳統方法相比，這些平台技術能夠加速疫苗設計和生產的調整，大幅縮短應對疫情的研發週期。除了感染疾病，mRNA平台也被研究用於癌症疫苗、自體免疫疾病和罕見遺傳疾病的研發，大大拓展了目標市場。目前，多家製造商正大力投資於平台多元化、擴大生產規模和加強分銷能力，使這些技術成為推動整個疫苗產業變革的驅動力。

疫苗的猶豫和虛假資訊宣傳活動

民眾對疫苗安全性和有效性的持續質疑，即使在擁有成熟疾病預防記錄的先進醫療體系中，也導致疫苗接種率持續下降。社群媒體和網路社群放大了未經科學證實的說法，創造出資訊環境，在這種環境下，錯誤訊息的傳播速度遠超準確的公共衛生訊息。這種不願接種疫苗的心理，導致麻疹在先前宣布根除的地區捲土重來，並在病毒持續變異的情況下，減緩了新冠病毒加強疫苗的分發。要克服這些行為障礙，需要大力投資社區參與、醫護人員培訓以及文化敏感的傳播策略——這些非技術性挑戰僅靠傳統的藥物治療方法無法解決。

新冠疫情的影響：

新冠疫情透過前所未有的合作、加速的資金籌措和意識提升，從根本上改變了疫苗市場。監管機構引入了緊急使用授權和滾動審查流程，在不降低安全標準的前提下，將核准流程從數年縮短至數月。各國政府對生產能力的大規模投資，包括製藥公司之間的合作，使得全球數十億劑疫苗得以生產和分發。疫情也鞏固了成人疫苗接種在許多地區作為常規公共衛生措施的地位，從而持續推動了對加強劑的需求，並擴大了成人免疫接種計劃。這些結構性變化永久提高了疫苗的基線使用率，並加速了針對多種疾病的疫苗研發。

在預測期內，醫院領域預計將佔據最大的市場佔有率。

在預測期內，醫院預計將佔據最大的市場佔有率。這主要歸功於醫院擁有完善的基礎設施、訓練有素的醫護人員以及處理複雜疫苗接種方案（包括不良事件管理）的能力。醫院在新生兒疫苗接種、旅行前諮詢、職業健康計畫以及補種（針對先前漏種的疫苗）等方面發揮關鍵作用。醫院在醫療服務體系中的核心地位，尤其是在應對大規模緊急應變方面，使其成為常規和疫情免疫接種活動的重要合作夥伴。在醫院環境中整合免疫接種記錄和電子健康記錄（EHR）進一步鞏固了這一管道的主導地位，實現了更完善的追蹤和提醒系統，並促進了多種疫苗類型和接種計劃之間的協調。

在預測期內，零售藥局領域預計將呈現最高的複合年成長率。

在預測期內，零售藥局領域預計將呈現最高的成長率，反映出人們越來越傾向於在傳統醫療機構之外尋求便捷的疫苗接種服務。藥局提供更長的營業時間、無需預約的接種服務以及社區位置，顯著降低了在職成年人和農村居民接種疫苗的門檻。許多國家正在推出法規，擴大藥劑師的執業範圍，允許他們接種種類日益豐富的疫苗，包括流感疫苗、肺炎球菌疫苗、帶狀皰疹疫苗和新冠加強疫苗。與醫院相比，零售藥局模式的營運成本更低，因此能夠提供更具競爭力的價格。此外，成熟的藥品管理系統能夠與疫苗接種服務無縫銜接，打造高效且以患者為中心的疫苗接種平台，並持續獲得監管機構的核准和消費者的支持。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其先進的醫療保健基礎設施、較高的人均醫療保健支出以及覆蓋所有年齡段的完善免疫接種計劃。該地區聚集了許多主要的疫苗生產商和研究機構，促進了持續創新，並維持了常規疫苗和疫情疫苗的穩健供應鏈。強大的官民合作關係，包括廣泛的藥房疫苗接種網路，提供了多種網路基地台，確保了高接種率。政府資助的項目，例如“兒童疫苗計劃”，消除了弱勢群體接種疫苗的費用障礙，而強制性私人保險則確保了成年人獲得全面的保障。這個成熟的生態系統，加上對下一代疫苗研發的持續投入，預計將在整個預測期內鞏固北美的市場領導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於龐大且不斷成長的人口、政府免疫接種工作的擴大以及多個國家醫療基礎設施的改善。中國、印度和東南亞國家的快速經濟成長提高了國內疫苗生產能力，並增加了對公共衛生領域的投資。大規模的新生兒群體將維持對兒童疫苗的需求，而人口老化則需要擴大成人免疫接種計劃，以預防流感、肺炎鏈球菌感染和帶狀皰疹。區域內促進國內疫苗生產的舉措，包括印度塞拉姆研究所的大規模生產設施，正在減少對進口的依賴，並提高供應穩定性。與支持亞太低收入國家擴大免疫接種的國際組織夥伴關係，進一步加速了區域市場的成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球疫苗市場：依疫苗類型分類

  • 活病毒疫苗
  • 去活化疫苗
  • 次單位疫苗
    • 重組疫苗
    • 結合疫苗
  • 類毒素疫苗
  • 藥效疫苗
  • 病毒載體疫苗
  • DNA疫苗
  • 聯合疫苗

第6章：全球疫苗市場：以價型分類

  • 單價疫苗
  • 多價疫苗

第7章：全球疫苗市場：依疾病適應症分類

  • 病毒性疾病
    • 流感
    • COVID-19
    • 肝炎
    • HPV
    • 麻疹、腮腺炎、德國德國麻疹（MMR）
    • 輪狀病毒
    • 水痘
    • 呼吸道融合細胞病毒（RSV）
    • 其他病毒性疾病
  • 細菌性疾病
    • 肺炎鏈球菌感染
    • 病菌感染
    • 白喉、破傷風、百日咳三重疫苗（DTP）
    • 結核病（卡介苗）
    • 其他細菌性疾病
  • 癌症疫苗
  • 過敏疫苗
  • 其他治療性疫苗

第8章 全球疫苗市場：依給藥途徑分類

  • 腸外
  • 口服
  • 鼻內

第9章 全球疫苗市場：依年齡層別分類

  • 兒童疫苗
  • 成人疫苗

第10章 全球疫苗市場：依生產模式分類

  • 內部生產
  • 契約製造組織（CMO）
  • 公共部門製造業

第11章：全球疫苗市場：依儲存和分銷分類

  • 標準低溫運輸疫苗
  • 超低溫鏈疫苗
  • 耐熱疫苗

第12章 全球疫苗市場：依最終用戶分類

  • 醫院
  • 診所
  • 疫苗接種中心
  • 政府疫苗接種計劃
  • 非政府組織和國際組織

第13章 全球疫苗市場：依通路分類

  • 政府供應計劃
  • 向機構供應
  • 零售藥房
  • 其他頻道

第14章 全球疫苗市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第15章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第16章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第17章：公司簡介

  • Pfizer Inc
  • Moderna Inc
  • Johnson and Johnson
  • GlaxoSmithKline plc
  • Sanofi SA
  • Merck and Co Inc
  • AstraZeneca plc
  • Bharat Biotech International Limited
  • Serum Institute of India Pvt Ltd
  • Sinovac Biotech Ltd
  • Sinopharm Group Co Ltd
  • CSL Limited
  • Novavax Inc
  • BioNTech SE
  • Takeda Pharmaceutical Company Limited
  • Emergent BioSolutions Inc
Product Code: SMRC35973

According to Stratistics MRC, the Global Vaccine Market is accounted for $91.4 billion in 2026 and is expected to reach $155.9 billion by 2034 growing at a CAGR of 6.9% during the forecast period. Vaccines are biological preparations that provide active acquired immunity to specific infectious diseases, playing a critical role in global public health through disease prevention and eradication efforts. The market encompasses a wide range of vaccine types including pediatric, adult, influenza, COVID-19, travel, and therapeutic vaccines targeting various infectious conditions. Increasing disease outbreaks, growing geriatric populations susceptible to infections, continuous research investments, and expanding immunization programs across developing nations collectively drive the sustained expansion of this essential healthcare market.

Market Dynamics:

Driver:

Rising incidence of infectious diseases and pandemic threats

Recurring outbreaks of infectious diseases including measles, dengue, Ebola, and novel influenza strains continuously reinforce the critical importance of vaccination programs worldwide. The recent COVID-19 pandemic demonstrated both the devastating economic and health impacts of emerging pathogens and the remarkable potential of rapid vaccine development platforms. This heightened awareness has translated into sustained government funding, accelerated regulatory pathways, and unprecedented public acceptance of immunization. Emerging economies facing dual burdens of endemic and emerging infectious diseases represent particularly strong demand drivers, as healthcare infrastructure expansion increasingly prioritizes preventative medicine over reactive treatment approaches.

Restraint:

High costs of vaccine development and cold chain logistics

Developing a single new vaccine typically requires ten to fifteen years and investments exceeding one billion dollars, creating substantial barriers for smaller manufacturers and emerging market entrants. The stringent regulatory environment demands extensive clinical trials across diverse populations, further escalating development timelines and financial requirements. Additionally, the temperature-sensitive nature of most vaccines necessitates sophisticated cold chain infrastructure from manufacturing facilities to final administration points, representing significant logistical challenges in remote and resource-limited settings. These combined cost pressures limit market accessibility, particularly for vaccines targeting diseases prevalent primarily in low-income regions with limited ability to pay premium pricing.

Opportunity:

Expansion of mRNA and novel platform technologies

The remarkable success of mRNA vaccines during the COVID-19 pandemic has revolutionized vaccine development paradigms, opening unprecedented opportunities for rapid response to emerging threats and previously challenging targets. These platform technologies enable faster design and manufacturing adaptation compared to traditional approaches, substantially reducing development timelines for pandemic responses. Beyond infectious diseases, mRNA platforms are being investigated for therapeutic cancer vaccines, autoimmune conditions, and rare genetic disorders, dramatically expanding the addressable market. Multiple manufacturers are now investing heavily in platform diversification, manufacturing scale-up, and distribution capabilities, positioning these technologies as transformative forces across the broader vaccine landscape.

Threat:

Vaccine hesitancy and misinformation campaigns

Persistent public skepticism regarding vaccine safety and efficacy continues to undermine immunization coverage rates even in well-developed healthcare systems with established track records of disease prevention. Social media platforms and online communities amplify scientifically unsubstantiated claims, creating information ecosystems where misinformation spreads faster than accurate public health messaging. This hesitancy has contributed to resurgent measles outbreaks in regions previously declared elimination-free and slowed COVID-19 booster adoption despite ongoing viral evolution. Addressing these behavioral barriers requires substantial investments in community engagement, healthcare worker training, and culturally tailored communication strategies, representing non-technical challenges that traditional pharmaceutical approaches cannot alone resolve.

Covid-19 Impact:

The COVID-19 pandemic fundamentally transformed the vaccine market through unprecedented collaboration, funding acceleration, and public awareness. Regulatory bodies implemented emergency use authorizations and rolling review processes, compressing traditional multi-year approval timelines into months without compromising safety standards. Massive government investments in manufacturing capacity, including partnerships between competing pharmaceutical companies, enabled billions of doses to be produced and distributed globally. The pandemic also normalized adult vaccination as a routine public health practice in many regions, creating sustained demand for booster doses and expanded adult immunization schedules. These structural changes have permanently elevated baseline vaccine utilization and accelerated pipeline development across multiple disease targets.

The Hospitals segment is expected to be the largest during the forecast period

The Hospitals segment is expected to account for the largest market share during the forecast period, driven by their comprehensive infrastructure, trained medical personnel, and ability to handle complex vaccination scenarios including adverse reaction management. Hospitals serve as primary vaccination sites for newborns, pre-travel consultations, occupational health programs, and catch-up immunizations for previously missed doses. Their centralized role in healthcare delivery systems, particularly in managing large-scale emergency responses, makes them indispensable partners in routine and pandemic immunization efforts. The integration of vaccination records with electronic health records in hospital settings further strengthens this channel's dominance by enabling better tracking, reminder systems, and coordination across multiple vaccine types and schedules.

The Retail Pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Retail Pharmacies segment is predicted to witness the highest growth rate, reflecting the shift toward convenient, accessible vaccination services outside traditional medical settings. Pharmacies offer extended hours, walk-in appointments, and locations embedded within communities, significantly reducing access barriers for working adults and rural populations. Expanded scope-of-practice regulations across multiple countries now authorize pharmacists to administer a growing range of vaccines, including influenza, pneumococcal, shingles, and COVID-19 boosters. The retail pharmacy model's lower overhead costs compared to hospital settings enable more competitive pricing, while established medication management systems integrate seamlessly with immunization services, creating efficient, patient-centered delivery platforms that continue gaining regulatory approval and consumer acceptance.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by advanced healthcare infrastructure, high per capita healthcare spending, and established immunization schedules across all age groups. The region's concentration of major vaccine manufacturers and research institutions drives continuous innovation and maintains robust supply chains for routine and pandemic vaccines. Strong public-private partnerships, including extensive pharmacy-based administration networks, create multiple access points ensuring high coverage rates. Government-funded programs like Vaccines for Children eliminate cost barriers for vulnerable populations, while private insurance mandates ensure comprehensive adult coverage. This mature ecosystem, combined with ongoing investments in next-generation vaccine development, reinforces North America's market leadership throughout the forecast timeline.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by large and growing populations, expanding government immunization commitments, and improving healthcare infrastructure across multiple countries. Rapid economic growth in China, India, and Southeast Asian nations has enabled increased domestic vaccine manufacturing capacity and public health investments. Significant birth cohorts create sustained demand for pediatric vaccines, while aging populations require expanded adult immunization programs against influenza, pneumococcal disease, and herpes zoster. Regional initiatives promoting indigenous vaccine production, including the Serum Institute of India's massive manufacturing scale, reduce import dependence and improve supply security. International organization partnerships supporting immunization expansion in lower-income Asia Pacific countries further accelerate regional market growth.

Key players in the market

Some of the key players in Vaccine Market include Pfizer Inc, Moderna Inc, Johnson and Johnson, GlaxoSmithKline plc, Sanofi SA, Merck and Co Inc, AstraZeneca plc, Bharat Biotech International Limited, Serum Institute of India Pvt Ltd, Sinovac Biotech Ltd, Sinopharm Group Co Ltd, CSL Limited, Novavax Inc, BioNTech SE, Takeda Pharmaceutical Company Limited, and Emergent BioSolutions Inc.

Key Developments:

In April 2026, The European Commission approved ENFLONSIA (clesrovimab) for the prevention of RSV lower respiratory tract disease in infants during their first RSV season.

In March 2026, GSK's Respiratory Syncytial Virus (RSV) vaccine, Arexvy, received FDA approval for an expanded age indication; covering adults aged 18-49 who are at increased risk of severe infection.

In December 2025, CSL officially opened its new $1 billion world-class vaccine and antivenom manufacturing facility in Melbourne, Australia, significantly boosting onshore cell-based influenza vaccine production.

Vaccine Types Covered:

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines

Valency Types Covered:

  • Monovalent Vaccines
  • Multivalent Vaccines

Disease Indications Covered:

  • Viral Diseases
  • Bacterial Diseases
  • Cancer Vaccines
  • Allergy Vaccines
  • Other Therapeutic Vaccines

Route of Administrations Covered:

  • Parenteral
  • Oral
  • Intranasal

Age Groups Covered:

  • Pediatric Vaccines
  • Adult Vaccines

Manufacturing Models Covered:

  • In-House Manufacturing
  • Contract Manufacturing Organizations (CMOs)
  • Public Sector Manufacturing

Storage & Logistics Covered:

  • Standard Cold Chain Vaccines
  • Ultra-Cold Chain Vaccines
  • Thermostable Vaccines

End Users Covered:

  • Hospitals
  • Clinics
  • Vaccination Centers
  • Government Immunization Programs
  • NGOs & International Organizations

Distribution Channels Covered:

  • Government Supply Programs
  • Institutional Supply
  • Retail Pharmacies
  • Other Channels

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Vaccine Market, By Vaccine Type

  • 5.1 Live Attenuated Vaccines
  • 5.2 Inactivated Vaccines
  • 5.3 Subunit Vaccines
    • 5.3.1 Recombinant Vaccines
    • 5.3.2 Conjugate Vaccines
  • 5.4 Toxoid Vaccines
  • 5.5 mRNA Vaccines
  • 5.6 Viral Vector Vaccines
  • 5.7 DNA Vaccines
  • 5.8 Combination Vaccines

6 Global Vaccine Market, By Valency Type

  • 6.1 Monovalent Vaccines
  • 6.2 Multivalent Vaccines

7 Global Vaccine Market, By Disease Indication

  • 7.1 Viral Diseases
    • 7.1.1 Influenza
    • 7.1.2 COVID-19
    • 7.1.3 Hepatitis
    • 7.1.4 HPV
    • 7.1.5 Measles, Mumps, Rubella (MMR)
    • 7.1.6 Rotavirus
    • 7.1.7 Varicella
    • 7.1.8 Respiratory Syncytial Virus (RSV)
    • 7.1.9 Other Viral Diseases
  • 7.2 Bacterial Diseases
    • 7.2.1 Pneumococcal Diseases
    • 7.2.2 Meningococcal Diseases
    • 7.2.3 DTP (Diphtheria, Tetanus, Pertussis)
    • 7.2.4 Tuberculosis (BCG)
    • 7.2.5 Other Bacterial Diseases
  • 7.3 Cancer Vaccines
  • 7.4 Allergy Vaccines
  • 7.5 Other Therapeutic Vaccines

8 Global Vaccine Market, By Route of Administration

  • 8.1 Parenteral
  • 8.2 Oral
  • 8.3 Intranasal

9 Global Vaccine Market, By Age Group

  • 9.1 Pediatric Vaccines
  • 9.2 Adult Vaccines

10 Global Vaccine Market, By Manufacturing Model

  • 10.1 In-House Manufacturing
  • 10.2 Contract Manufacturing Organizations (CMOs)
  • 10.3 Public Sector Manufacturing

11 Global Vaccine Market, By Storage & Logistics

  • 11.1 Standard Cold Chain Vaccines
  • 11.2 Ultra-Cold Chain Vaccines
  • 11.3 Thermostable Vaccines

12 Global Vaccine Market, By End User

  • 12.1 Hospitals
  • 12.2 Clinics
  • 12.3 Vaccination Centers
  • 12.4 Government Immunization Programs
  • 12.5 NGOs & International Organizations

13 Global Vaccine Market, By Distribution Channel

  • 13.1 Government Supply Programs
  • 13.2 Institutional Supply
  • 13.3 Retail Pharmacies
  • 13.4 Other Channels

14 Global Vaccine Market, By Geography

  • 14.1 North America
    • 14.1.1 United States
    • 14.1.2 Canada
    • 14.1.3 Mexico
  • 14.2 Europe
    • 14.2.1 United Kingdom
    • 14.2.2 Germany
    • 14.2.3 France
    • 14.2.4 Italy
    • 14.2.5 Spain
    • 14.2.6 Netherlands
    • 14.2.7 Belgium
    • 14.2.8 Sweden
    • 14.2.9 Switzerland
    • 14.2.10 Poland
    • 14.2.11 Rest of Europe
  • 14.3 Asia Pacific
    • 14.3.1 China
    • 14.3.2 Japan
    • 14.3.3 India
    • 14.3.4 South Korea
    • 14.3.5 Australia
    • 14.3.6 Indonesia
    • 14.3.7 Thailand
    • 14.3.8 Malaysia
    • 14.3.9 Singapore
    • 14.3.10 Vietnam
    • 14.3.11 Rest of Asia Pacific
  • 14.4 South America
    • 14.4.1 Brazil
    • 14.4.2 Argentina
    • 14.4.3 Colombia
    • 14.4.4 Chile
    • 14.4.5 Peru
    • 14.4.6 Rest of South America
  • 14.5 Rest of the World (RoW)
    • 14.5.1 Middle East
      • 14.5.1.1 Saudi Arabia
      • 14.5.1.2 United Arab Emirates
      • 14.5.1.3 Qatar
      • 14.5.1.4 Israel
      • 14.5.1.5 Rest of Middle East
    • 14.5.2 Africa
      • 14.5.2.1 South Africa
      • 14.5.2.2 Egypt
      • 14.5.2.3 Morocco
      • 14.5.2.4 Rest of Africa

15 Strategic Market Intelligence

  • 15.1 Industry Value Network and Supply Chain Assessment
  • 15.2 White-Space and Opportunity Mapping
  • 15.3 Product Evolution and Market Life Cycle Analysis
  • 15.4 Channel, Distributor, and Go-to-Market Assessment

16 Industry Developments and Strategic Initiatives

  • 16.1 Mergers and Acquisitions
  • 16.2 Partnerships, Alliances, and Joint Ventures
  • 16.3 New Product Launches and Certifications
  • 16.4 Capacity Expansion and Investments
  • 16.5 Other Strategic Initiatives

17 Company Profiles

  • 17.1 Pfizer Inc
  • 17.2 Moderna Inc
  • 17.3 Johnson and Johnson
  • 17.4 GlaxoSmithKline plc
  • 17.5 Sanofi SA
  • 17.6 Merck and Co Inc
  • 17.7 AstraZeneca plc
  • 17.8 Bharat Biotech International Limited
  • 17.9 Serum Institute of India Pvt Ltd
  • 17.10 Sinovac Biotech Ltd
  • 17.11 Sinopharm Group Co Ltd
  • 17.12 CSL Limited
  • 17.13 Novavax Inc
  • 17.14 BioNTech SE
  • 17.15 Takeda Pharmaceutical Company Limited
  • 17.16 Emergent BioSolutions Inc

List of Tables

  • Table 1 Global Vaccine Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Vaccine Market Outlook, By Vaccine Type (2023-2034) ($MN)
  • Table 3 Global Vaccine Market Outlook, By Live Attenuated Vaccines (2023-2034) ($MN)
  • Table 4 Global Vaccine Market Outlook, By Inactivated Vaccines (2023-2034) ($MN)
  • Table 5 Global Vaccine Market Outlook, By Subunit Vaccines (2023-2034) ($MN)
  • Table 6 Global Vaccine Market Outlook, By Recombinant Vaccines (2023-2034) ($MN)
  • Table 7 Global Vaccine Market Outlook, By Conjugate Vaccines (2023-2034) ($MN)
  • Table 8 Global Vaccine Market Outlook, By Toxoid Vaccines (2023-2034) ($MN)
  • Table 9 Global Vaccine Market Outlook, By mRNA Vaccines (2023-2034) ($MN)
  • Table 10 Global Vaccine Market Outlook, By Viral Vector Vaccines (2023-2034) ($MN)
  • Table 11 Global Vaccine Market Outlook, By DNA Vaccines (2023-2034) ($MN)
  • Table 12 Global Vaccine Market Outlook, By Combination Vaccines (2023-2034) ($MN)
  • Table 13 Global Vaccine Market Outlook, By Valency Type (2023-2034) ($MN)
  • Table 14 Global Vaccine Market Outlook, By Monovalent Vaccines (2023-2034) ($MN)
  • Table 15 Global Vaccine Market Outlook, By Multivalent Vaccines (2023-2034) ($MN)
  • Table 16 Global Vaccine Market Outlook, By Disease Indication (2023-2034) ($MN)
  • Table 17 Global Vaccine Market Outlook, By Viral Diseases (2023-2034) ($MN)
  • Table 18 Global Vaccine Market Outlook, By Influenza (2023-2034) ($MN)
  • Table 19 Global Vaccine Market Outlook, By COVID-19 (2023-2034) ($MN)
  • Table 20 Global Vaccine Market Outlook, By Hepatitis (2023-2034) ($MN)
  • Table 21 Global Vaccine Market Outlook, By HPV (2023-2034) ($MN)
  • Table 22 Global Vaccine Market Outlook, By Measles, Mumps, Rubella (MMR) (2023-2034) ($MN)
  • Table 23 Global Vaccine Market Outlook, By Rotavirus (2023-2034) ($MN)
  • Table 24 Global Vaccine Market Outlook, By Varicella (2023-2034) ($MN)
  • Table 25 Global Vaccine Market Outlook, By Respiratory Syncytial Virus (RSV) (2023-2034) ($MN)
  • Table 26 Global Vaccine Market Outlook, By Other Viral Diseases (2023-2034) ($MN)
  • Table 27 Global Vaccine Market Outlook, By Bacterial Diseases (2023-2034) ($MN)
  • Table 28 Global Vaccine Market Outlook, By Pneumococcal Diseases (2023-2034) ($MN)
  • Table 29 Global Vaccine Market Outlook, By Meningococcal Diseases (2023-2034) ($MN)
  • Table 30 Global Vaccine Market Outlook, By DTP (Diphtheria, Tetanus, Pertussis) (2023-2034) ($MN)
  • Table 31 Global Vaccine Market Outlook, By Tuberculosis (BCG) (2023-2034) ($MN)
  • Table 32 Global Vaccine Market Outlook, By Other Bacterial Diseases (2023-2034) ($MN)
  • Table 33 Global Vaccine Market Outlook, By Cancer Vaccines (2023-2034) ($MN)
  • Table 34 Global Vaccine Market Outlook, By Allergy Vaccines (2023-2034) ($MN)
  • Table 35 Global Vaccine Market Outlook, By Other Therapeutic Vaccines (2023-2034) ($MN)
  • Table 36 Global Vaccine Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 37 Global Vaccine Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 38 Global Vaccine Market Outlook, By Oral (2023-2034) ($MN)
  • Table 39 Global Vaccine Market Outlook, By Intranasal (2023-2034) ($MN)
  • Table 40 Global Vaccine Market Outlook, By Age Group (2023-2034) ($MN)
  • Table 41 Global Vaccine Market Outlook, By Pediatric Vaccines (2023-2034) ($MN)
  • Table 42 Global Vaccine Market Outlook, By Adult Vaccines (2023-2034) ($MN)
  • Table 43 Global Vaccine Market Outlook, By Manufacturing Model (2023-2034) ($MN)
  • Table 44 Global Vaccine Market Outlook, By In-House Manufacturing (2023-2034) ($MN)
  • Table 45 Global Vaccine Market Outlook, By Contract Manufacturing Organizations (CMOs) (2023-2034) ($MN)
  • Table 46 Global Vaccine Market Outlook, By Public Sector Manufacturing (2023-2034) ($MN)
  • Table 47 Global Vaccine Market Outlook, By Storage & Logistics (2023-2034) ($MN)
  • Table 48 Global Vaccine Market Outlook, By Standard Cold Chain Vaccines (2023-2034) ($MN)
  • Table 49 Global Vaccine Market Outlook, By Ultra-Cold Chain Vaccines (2023-2034) ($MN)
  • Table 50 Global Vaccine Market Outlook, By Thermostable Vaccines (2023-2034) ($MN)
  • Table 51 Global Vaccine Market Outlook, By End User (2023-2034) ($MN)
  • Table 52 Global Vaccine Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 53 Global Vaccine Market Outlook, By Clinics (2023-2034) ($MN)
  • Table 54 Global Vaccine Market Outlook, By Vaccination Centers (2023-2034) ($MN)
  • Table 55 Global Vaccine Market Outlook, By Government Immunization Programs (2023-2034) ($MN)
  • Table 56 Global Vaccine Market Outlook, By NGOs & International Organizations (2023-2034) ($MN)
  • Table 57 Global Vaccine Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 58 Global Vaccine Market Outlook, By Government Supply Programs (2023-2034) ($MN)
  • Table 59 Global Vaccine Market Outlook, By Institutional Supply (2023-2034) ($MN)
  • Table 60 Global Vaccine Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 61 Global Vaccine Market Outlook, By Other Channels (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.